drug

carbidopa

Marketedupdated 3mo ago

by Bausch Health Americas Inc

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 24 investigational indications.

indications

investigational

Parkinson's Disease

all catalysts(100)

approval · 100

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET CR (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

SINEMET (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

DUOPA (CARBIDOPA) — FDA approval

DUOPA (CARBIDOPA) — FDA approval

DUOPA (CARBIDOPA) — FDA approval

DUOPA (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

STALEVO 75 (CARBIDOPA) — FDA approval

carbidopa

→

view all 100 catalysts →

Trials studying carbidopa

phase3A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuationscompletedn=165
phase1A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participantsrecruitingn=12
—Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Diseaseactive not recruitingn=100
phase2Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuationscompletedn=61
phase1A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patientscompletedn=8
phase2Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopacompletedn=20
phase1A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjectscompletedn=35
phase2Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgiacompletedn=122

more trials →

News(0)

no news has mentioned this drug yet

Data sources

openFDA · ClinicalTrials.gov

last refreshed 18m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

carbidopa

indications

all catalysts(100)

Trials studying carbidopa

News(0)

Report a data issue

comments(0)

carbidopa

indications

all catalysts(100)

Trials studying carbidopa

News(0)

Report a data issue

comments(0)